[go: up one dir, main page]

NO882341L - Ekspresjon av humant proapolipoprotein a-i. - Google Patents

Ekspresjon av humant proapolipoprotein a-i.

Info

Publication number
NO882341L
NO882341L NO88882341A NO882341A NO882341L NO 882341 L NO882341 L NO 882341L NO 88882341 A NO88882341 A NO 88882341A NO 882341 A NO882341 A NO 882341A NO 882341 L NO882341 L NO 882341L
Authority
NO
Norway
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
humant
Prior art date
Application number
NO88882341A
Other languages
English (en)
Other versions
NO882341D0 (no
NO179253C (no
NO179253B (no
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO882341D0 publication Critical patent/NO882341D0/no
Publication of NO882341L publication Critical patent/NO882341L/no
Publication of NO179253B publication Critical patent/NO179253B/no
Publication of NO179253C publication Critical patent/NO179253C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NO882341A 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet NO179253C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (4)

Publication Number Publication Date
NO882341D0 NO882341D0 (no) 1988-05-27
NO882341L true NO882341L (no) 1988-11-29
NO179253B NO179253B (no) 1996-05-28
NO179253C NO179253C (no) 1996-09-04

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882341A NO179253C (no) 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet

Country Status (33)

Country Link
US (1) US5059528A (no)
EP (1) EP0293357B1 (no)
JP (1) JP2634193B2 (no)
KR (1) KR970000808B1 (no)
CN (1) CN1031892C (no)
AT (1) ATE89006T1 (no)
AU (1) AU615654B2 (no)
CA (1) CA1323851C (no)
CY (1) CY1809A (no)
CZ (1) CZ283648B6 (no)
DD (1) DD291093A5 (no)
DE (1) DE3880739T2 (no)
DK (1) DK175686B1 (no)
EG (1) EG19101A (no)
ES (1) ES2054878T3 (no)
FI (1) FI100056B (no)
GB (1) GB8712540D0 (no)
HK (1) HK137794A (no)
HU (1) HU204562B (no)
IE (1) IE62422B1 (no)
IL (1) IL86480A (no)
LT (1) LT3600B (no)
LV (1) LV5288A3 (no)
NO (1) NO179253C (no)
NZ (1) NZ224808A (no)
PL (1) PL158064B1 (no)
PT (1) PT87562B (no)
RU (1) RU2009198C1 (no)
SG (1) SG131594G (no)
SK (1) SK279166B6 (no)
SU (1) SU1834904A3 (no)
UA (1) UA19765A (no)
ZA (1) ZA883824B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
WO1992010760A1 (en) * 1990-11-30 1992-06-25 Monoclonetics International, Incorporated Methods for the diagnosis of chronic lower back and cervical pain
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007023476A2 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
MX339820B (es) * 2008-10-03 2016-06-13 Curna Inc Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
SG10201901089TA (en) 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
NZ711583A (en) 2009-05-05 2017-03-31 Arbutus Biopharma Corp Lipid compositions
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
SMT202100696T1 (it) 2009-06-10 2022-01-10 Arbutus Biopharma Corp Formulazione lipidica migliorata
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
NZ600725A (en) 2009-12-18 2015-08-28 Univ British Colombia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
JP6219170B2 (ja) 2011-02-07 2017-10-25 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
JP6387084B2 (ja) * 2013-05-01 2018-09-05 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アポリポタンパク質ｃ−ｉｉｉの発現を調節するための組成物および方法
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
CN108473990A (zh) * 2016-10-27 2018-08-31 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
EP3668549B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Apomers
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
EP4221686A2 (en) 2020-10-01 2023-08-09 Abionyx Pharma SA Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
AU580145B2 (en) 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
EP0239631A4 (en) 1985-10-04 1989-01-12 Biotech Res Partners Ltd RECOMBINANT APOLIPOPROTEINS AND METHODS.
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
AU8273987A (en) * 1986-10-29 1988-05-25 Biotechnology Research Partners Limited Apoai-ciii-aiv, apoaii apob , apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
LT3600B (en) 1995-12-27
NO882341D0 (no) 1988-05-27
DK289688A (da) 1988-11-29
DD291093A5 (de) 1991-06-20
UA19765A (uk) 1997-12-25
IL86480A (en) 1992-08-18
KR880014110A (ko) 1988-12-22
EP0293357B1 (fr) 1993-05-05
SK363888A3 (en) 1998-07-08
FI882456A0 (fi) 1988-05-25
DE3880739D1 (de) 1993-06-09
CZ283648B6 (cs) 1998-05-13
US5059528A (en) 1991-10-22
JP2634193B2 (ja) 1997-07-23
PT87562B (pt) 1992-09-30
ATE89006T1 (de) 1993-05-15
FI100056B (fi) 1997-09-15
DE3880739T2 (de) 1993-08-19
ZA883824B (en) 1989-02-22
NZ224808A (en) 1990-01-29
EP0293357A1 (fr) 1988-11-30
HUT47153A (en) 1989-01-30
CZ363888A3 (cs) 1998-02-18
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
JPS6416589A (en) 1989-01-20
ES2054878T3 (es) 1994-08-16
SG131594G (en) 1995-01-13
CA1323851C (en) 1993-11-02
IE62422B1 (en) 1995-02-08
PT87562A (pt) 1989-05-31
RU2009198C1 (ru) 1994-03-15
HU204562B (en) 1992-01-28
SU1834904A3 (ru) 1993-08-15
FI882456A (fi) 1988-11-29
PL158064B1 (pl) 1992-07-31
CY1809A (en) 1995-10-20
LTIP828A (en) 1995-02-27
NO179253C (no) 1996-09-04
PL272698A1 (en) 1989-03-06
LV5288A3 (lv) 1993-10-10
IL86480A0 (en) 1988-11-15
CN88103118A (zh) 1988-12-14
CN1031892C (zh) 1996-05-29
KR970000808B1 (en) 1997-01-20
AU615654B2 (en) 1991-10-10
HK137794A (en) 1994-12-16
AU1672388A (en) 1988-12-01
EG19101A (en) 1994-09-29
NO179253B (no) 1996-05-28
SK279166B6 (sk) 1998-07-08
IE881597L (en) 1988-11-28
DK175686B1 (da) 2005-01-17

Similar Documents

Publication Publication Date Title
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
NO940736D0 (no) DNA sekvenser som koder for gelonin polypeptid
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DE69318716D1 (de) Anti-Katze Immundefiziensvirus (FIV) Impfstoffe
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
ATE188997T1 (de) Klonierung von malaria-spezifischen dna- sequenzen:isolierung des gens für das 140 kd protein
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees